Breast Cancer

Data from CAPItello-291 support the approval of capivasertib/fulvestrant for ER-positive, HER2-negative breast cancer in the European Union.

Capivasertib's safety profile in the CAPItello-290 trial was comparable with prior reports of the agent in advanced triple-negative breast cancer.

Patients with hormone receptor-positive breast cancer experienced weight loss when given a plant-based diet plus exercise.

The field of breast oncology is constantly evolving to include trial diversity and multidisciplinary care.

Tiffany A. Traina, MD, and Sherry Shen, MD, discussed barriers they have had to overcome throughout their oncology careers.

Patients with breast cancer or those who are survivors can be candidates for genetic testing, according to Brittany L. Bychkovsky, MD, MSc.

Secondary end points such as overall survival also appear to favor T-DXd among this breast cancer population in the phase 3 DESTINY-Breast06 trial.

Data also show a longer median time to deterioration for patients in the inavolisib arm in phase 3 INAVO120 trial.

A trend towards improved progression-free survival was not noted when pembrolizumab plus sacituzumab govitecan was used to treat patients with HR+ breast cancer.

Increased PFS was noted with abemaciclib plus fulvestrant vs fulvestrant alone in hormone receptor–positive, HER2-negative advanced breast cancer after disease progression on a CDK4/6 inhibitor and endocrine therapy.

Relapse-free survival was improved when anthracycline combo was used to treat MammaPrint high-2–risk, BluePrint Luminal B, HR-positive, HER2-negative breast cancer.

Tiffany A. Traina, MD, FASCO, and Sherry Shen, MD, share their personal and professional journeys to becoming breast oncologists at Memorial Sloan Kettering Cancer Center.

The FDA has set a Prescription Drug User Fee Act date of November 27, 2024, for the inavolisib-based combination in this breast cancer population.

Patients with BRCA-mutated breast cancer can safely undergo assisted reproductive techniques, according to an ESMO study.

Access to fertility preservation may help mitigate toxicity associated with chemotherapy and other agents in those with breast cancer.

Findings may support bilateral mastectomy as an alternative for symmetry following unilateral mastectomy for breast cancer.

Phase 1b data support the promising therapeutic benefit of vepdegestrant/palbociclib in ER-positive breast cancer regardless of ESR1 mutation status.

Data from the INAVO120 trial support the breakthrough therapy designation for inavolisib in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.